<?xml version='1.0' encoding='utf-8'?>
<document id="25505582"><sentence text="A clinical therapeutic protein drug-drug interaction study: coadministration of denosumab and midazolam in postmenopausal women with osteoporosis."><entity charOffset="94-103" id="DDI-PubMed.25505582.s1.e0" text="midazolam" /></sentence><sentence text="Drug-disease interactions involving therapeutic proteins that target cytokines and potentially impact cytochrome P450 (CYP) enzymes have been of increased interest to drug regulatory agencies and industry sponsors in recent years" /><sentence text=" This parallel-group open-label study evaluated the effects of the monoclonal antibody denosumab, an inhibitor of the cytokine RANKL, on the pharmacokinetics of the probe CYP3A4 substrate midazolam in postmenopausal women with osteoporosis" /><sentence text=" The pharmacokinetics of a 2 mg oral dose of midazolam was evaluated on days 1 and 16"><entity charOffset="45-54" id="DDI-PubMed.25505582.s4.e0" text="midazolam" /></sentence><sentence text=" Subjects in Group A received a 60 mg subcutaneous dose of denosumab on day 2, 2 weeks before the second midazolam dose, while subjects in Group B did not" /><sentence text=" For Group A (n = 17), point estimates for the ratio of least square means for midazolam exposures based on maximum observed plasma concentration (C max) and areas under the plasma concentration-time curve (AUCs) on day 16 versus day 1 ranged from 1" /><sentence text="02 to 1" /><sentence text="04 and 90% confidence intervals were within 0" /><sentence text="80-1" /><sentence text="25" /><sentence text=" No period effect was observed for Group B (n = 8)" /><sentence text=" Midazolam and denosumab coadministration was safe and well tolerated"><entity charOffset="1-10" id="DDI-PubMed.25505582.s12.e0" text="Midazolam" /><entity charOffset="15-24" id="DDI-PubMed.25505582.s12.e1" text="denosumab" /><pair ddi="false" e1="DDI-PubMed.25505582.s12.e0" e2="DDI-PubMed.25505582.s12.e0" /><pair ddi="false" e1="DDI-PubMed.25505582.s12.e0" e2="DDI-PubMed.25505582.s12.e1" /></sentence><sentence text=" Inhibition of the cytokine RANKL by denosumab does not affect CYP3A4 in postmenopausal women with osteoporosis and will not alter the pharmacokinetics of drugs metabolized by this enzyme" /><sentence text=" These results are consistent with data suggesting that RANKL does not impact markers of inflammation and represent the first clinical data demonstrating a lack of effect on CYP3A4 of a therapeutic protein that is a cytokine modulator" /><sentence text=" " /></document>